Plain-English translation of NCT06577272 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are building a prediction tool to identify which patients with hepatocellular carcinoma (liver cancer) are at highest risk of cancer recurrence after radiofrequency ablation (RFA)—a heat-based treatment that kills tumors. By studying data from thousands of patients, doctors hope to better understand which patients need closer monitoring or additional treatment after their ablation procedure.
Even after successful heat ablation treatment, many liver cancer patients experience cancer recurrence, which reduces their long-term survival and quality of life. This study exists to help doctors predict who is at high risk of recurrence so they can provide better, more personalized follow-up care.
If you join this study, researchers will review your medical records and imaging scans from before and after your ablation treatment. You'll complete a questionnaire about your health history and symptoms. There are no new treatments or procedures—the study simply collects information from your existing medical care to help build a prediction tool that will benefit future patients.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China